Simeon George, SR One CEO
Venture investing without the GSK tie-up? Simeon George and the SR One team score a $600M fund to pave the way forward
Over the past year, Simeon George has seen the market chill for biotech, scrambled a crisis team through a harrowing weekend as SVB’s collapse …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
